Efficacy of Dexmedetomidine VS Magnesium Sulphate With Bupivacaine in Erector Spinae Block for Thoracotomy Pain
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Bupivacaine, Bupivacaine + Magnesium, Bupivacaine + Dexmedetomidine.
- Who it may be relevant to
- Registry conditions: Analgesia. Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Analgesic Efficacy of Adding Dexmedetomidine VS Magnesium Sulphate as Adjuvants With Bupivacaine in Ultrasound-guided Erector Spinae Plane Block for Post Thoracotomy Pain
Overview
Postoperative pain management is considered an integral part of perioperative care in patients undergoing thoracotomy. In order to reduce these complications, multiple regional techniques have been developed for thoracotomy including Intercostal nerve block, Erectospinae plane block and serratus block. Multiple adjuvants have been used in regional analgesia including adrenaline,clonidine,magnesium sulphate,dexmedatomidine and opoids.
Interventions
- Drug Bupivacaine
Bupivacaine 0.25% - Drug Bupivacaine + Magnesium
Bupivacaine 0.25% + Magnesium - Drug Bupivacaine + Dexmedetomidine
Bupivacaine 0.25% + Dexmedetomidine
Primary outcome measures
- Total postoperative morphine consumption [Time frame: First 24 hours postoperatively]
Secondary outcome measures (1)
- Time to first postoperative rescue analgesia. [Time frame: First 24 hours postoperatively]
Eligibility criteria
Inclusion criteria
- Age from 18 to 65 years.
- Male and female sexes.
- ASA I-II.,III
- Cancer patients undergoing thoracotomy incisions
- Body mass index (BMI) from 18.5 to 30 kg/m2
Exclusion criteria
- Patient refusal
- Known allergy to any of the used drugs
- Low platelet count, any coagulation defect
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Walaa Y Elsabeeny — Cairo
Identifiers
NCT: NCT05851768 · N-80-2022/NSC